Navigation Links
Orexigen Therapeutics to Present at Upcoming Conferences
Date:2/9/2012

SAN DIEGO, Feb. 9, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences.  The details are as follows:

The 14th Annual BIO CEO & Investor Conference
Date:
February 13, 2012
Time:  1:30pm Eastern Time
Location:  Waldorf Astoria, New York
Speaker:  Michael Narachi, President and Chief Executive Officer

Leerink Swann Global Healthcare Conference
Date:
February 15, 2012
Time:  8:00am Eastern Time
Location:  Waldorf Astoria, New York
Speaker:  Michael Narachi, President and Chief Executive Officer

To listen to the live webcast or a replay of the presentations, please visit the Investor Relations section of the company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen TherapeuticsOrexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Contrave® has completed Phase 3 clinical trials for which a New Drug Application has been submitted and reviewed by the FDA, and the FDA has agreed to a SPA for the Contrave outcomes trial.  The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.Corporate Contacts: OrexigenOrexigen

MediaJay Hagan

Denise PowellChief Business Officer

WCG(858) 875-8673

(510)
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
2. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
3. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
4. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
5. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
6. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
7. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
8. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
9. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
10. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
11. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... LONDON , Sept. 2, 2014 ... Human Reproductive Technologies: Products and Global ... STUDY GOALS AND OBJECTIVES The objective of ... look at the market for reproductive technologies and ... and indication. The products in some markets are ...
(Date:9/2/2014)... DALLAS , Sept. 2, 2014 /PRNewswire-iReach/ -- ... Sodium Bicarbonate Industry" and "2014 Market Research Report ... research database. Photo - http://photos.prnewswire.com/prnh/20140902/141873 ... on Global Sodium Bicarbonate Industry" is a professional ... and Global Sodium Bicarbonate market. The ...
(Date:9/2/2014)... 02, 2014 The Little Company of ... constructed a new 290,000 square-foot West Pavilion patient tower, ... from Scranton Products for the nurse’s lounge near ... Little Company of Mary Hospital’s $180 million, four-year ... with the connection of the West Pavilion tower to ...
(Date:9/2/2014)... BELLINGHAM, Washington, USA (PRWEB) September 02, 2014 ... Year of Light and Light-based Technologies (IYL 2015) ... awards from SPIE, the international society for optics ... were presented to Levinson and Dudley along with other ... of the Society won by James Harrington, during a ...
Breaking Biology Technology:Human Reproductive Technologies: Products and Global Markets 2Human Reproductive Technologies: Products and Global Markets 3Human Reproductive Technologies: Products and Global Markets 4Human Reproductive Technologies: Products and Global Markets 5Human Reproductive Technologies: Products and Global Markets 6Human Reproductive Technologies: Products and Global Markets 7Human Reproductive Technologies: Products and Global Markets 8Human Reproductive Technologies: Products and Global Markets 9Human Reproductive Technologies: Products and Global Markets 10Human Reproductive Technologies: Products and Global Markets 11Human Reproductive Technologies: Products and Global Markets 12Human Reproductive Technologies: Products and Global Markets 13Human Reproductive Technologies: Products and Global Markets 14Human Reproductive Technologies: Products and Global Markets 15Human Reproductive Technologies: Products and Global Markets 16Human Reproductive Technologies: Products and Global Markets 17Sodium Bicarbonate Market & Ammonium Acetate Industry: China & Global Analysis 2Sodium Bicarbonate Market & Ammonium Acetate Industry: China & Global Analysis 3Sodium Bicarbonate Market & Ammonium Acetate Industry: China & Global Analysis 4Sodium Bicarbonate Market & Ammonium Acetate Industry: China & Global Analysis 5Tufftec® Lockers from Scranton Products Selected by Little Company of Mary Hospital Near Chicago to Create an Uplifting Environment 2Tufftec® Lockers from Scranton Products Selected by Little Company of Mary Hospital Near Chicago to Create an Uplifting Environment 3Levinson, Dudley Win SPIE Directors’ and President’s Awards 2Levinson, Dudley Win SPIE Directors’ and President’s Awards 3Levinson, Dudley Win SPIE Directors’ and President’s Awards 4
... Medical,Innovations, Inc. (Amex: IMA ), a leading ... consumer and professional markets, today,announced that Ron Zwanziger, ... Vice President, Finance, are scheduled to,attend the UBS ... at the Grand Hyatt New York in New ...
... HARBIN, China, Sept. 19 /Xinhua-PRNewswire-FirstCall/ -- China Sky ... Company") (Nasdaq: CSKI ), a,leading fully integrated ... of China ("PRC"), announced today that it,has successfully ... Europeenne (CE) certification, or CE mark, which indicates ...
... Minn., Sept. 18 MedNet Solutions, a global,eClinical ... announced the company,s active involvement as a speaker,sponsor ... Data Management,(SCDM) Annual Conference, to be held Sunday, ... The SCDM has invited Dr. Timothy Pratt, ...
Cached Biology Technology:China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification 2China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification 3MedNet Solutions to Speak, Sponsor and Exhibit at the 2008 Society of Clinical Data Management Annual Conference in Dallas 2
(Date:9/2/2014)... Md. -- A team of University of Maryland ... and other scientists say make possible new nanostructures ... clean energy and quantum computing advances to new ... issue of Nature Communications the Maryland ... strategy for hybrid nanostructures that uses a connector, ...
(Date:9/2/2014)... of Evolutionary Biology study provides evidence that ... diversification. , Investigators argue that the same factor ... Galpagos Islands is also responsible for the linguistic ... barriers that impede interaction between speech communities. Therefore, ... due to a reduction of linguistic contact. , ...
(Date:9/2/2014)... It,s hard to comprehend how bad the current rate ... knowing what it was before people came along. The ... times lower than scientists had thought, which means that ... are about 1,000 times more frequent now than in ... explanation from lead author Jurriaan de Vos, a Brown ...
Breaking Biology News(10 mins):New synthesis method may shape future of nanostructures, clean energy 2New synthesis method may shape future of nanostructures, clean energy 3Extinctions during human era worse than thought 2Extinctions during human era worse than thought 3
... growing brain, neural stem cells must strike a delicate balance ... multiply to provide plenty of starting materials and differentiation, ... the stem cells proliferate too much, they could grow out ... little, there may not be enough cells to become the ...
... Martinsried, Germany, October 01, 2009 / b3c newswire ... it added KinAffinity to its service portfolio. KinAffinity ... in a cell or tissue of interest. It ... a cellular proteome and thus overcomes the limitations ...
... researchers from the University of Maryland Center for Environmental ... to forecast the effects of environmental change on the ... a $620,000 grant from the National Science Foundation, will ... near Alexandria, Virginia. "Freshwater marshes are integral to ...
Cached Biology News:UNC study pinpoints gene controlling number of brain cells 2KINAXO launches KinAffinity services for efficient profiling of kinase inhibitors in cells or tissue 2
Mouse polyclonal antibody raised against a partial recombinant COASY. NCBI Entrez Gene ID = 80347...
... Polyclonal Antibody against Nonmuscle Myosin ... Purified Antibody (Stored in TBS + ... against the peptide SDVNETQPPQSE corresponding to ... chain isoform B (MHC-B) This antibody ...
... Factor XIII in both reduced and non-reduced forms. ... B-chain or human Factor XII. Factor XIII is ... of two subunits. Factor XIII-A is the catalytic ... Factor XIII is present in plasma as an ...
... DNAscope V is a fully integrated ... and image processing that deliver excellent quality ... a high quality microarray scanner that is ... for optimal background rejection and spatial resolution. ...
Biology Products: